The data presented herein is related to the article entitled "Trypanosoma cruzi immunoproteome: calpain-like CAP5.5 differentially detected throughout distinct stages of human Chagas disease cardiomyopathy" [1] . Electrophoretic analyses under denaturing and reducing conditions indicate that covalent immobilization of human IgG to Protein G magnetic beads by cross-linking with 50 mM dimethyl pimelimidate hinders the recognition of T. cruzi antigens in immunoprecipitation assays.
Specifications

Value of the data
The data indicate that the use of DMP for covalent immobilization of human IgG should be averted whenever possible in order to avoid loss of paratope properties;
For those restricted to DMP usage, the data establish that concentrations of DMP lower than 50 mM should be tested for covalent immobilization of polyclonal antibody samples;
The data may concern those interested in studying aspects that affect antigen-antibody complex formation;
These data may be relevant for researchers interested in disabling antigen recognition properties of human IgG.
Data
Immunoprecipitation assays were performed by covalent IgG immobilization with 50 mM DMP (dimethyl pimelimidate), which has an imidioester at each end that reacts with amine groups, forming a stable amidine bond [2] . IgG protein quantities equivalent to 10, 50 or 100% of matrix binding capacity (13 mg of IgG/mL of magnetic bead) were tested in combination with different ratios of parasite protein extract. SDS-PAGE analysis of fractions eluted in the cross-linking immunoprecipitation assays did not result in polypeptide chain detection, regardless of growing amounts of either IgG or parasite protein assayed ( Figs. 1 and 2 ).
Experimental design, materials and methods
Parasite protein sample preparation
Proteins were extracted from bloodstream trypomastigote forms of T. cruzi (Y strain) obtained by heart puncture from Swiss mice at the 7 th day post infection. Parasites were washed thrice with phosphate- buffered saline (PBS, pH 7.4) and centrifuged at 6500g for 10 min at 4°C each time. Proteins were then extracted combining lysis solution (20 mM Tris, 1% Nonidet P-40, 300 mM NaCl, 50 mM KCl pH 7.5, 10 μM E-64) containing CompleteMini protease inhibitor cocktail (Roche Applied Science, Indianapolis, EUA) with 10 cycles of freezing-thawing in liquid nitrogen. Next, fractionation was performed at 16,000g for 20 min at 4°C; the soluble fraction was collected and stored at -80°C [3] . Protein quantification was carried out with 2-D Quant Kit (GE Healthcare, Buckinghamshire, England).
Human IgG purification
Serum was collected from a Chagas disease carrier with diagnosed cardiomyopathy stage C [4] assisted at the "Ambulatório de Doença de Chagas e InsuficiênciaCardíaca", coordinated by the Prof. Luiz Tavares Cardiologic Emergency Room of Pernambuco (PROCAPE) of the University of Pernambuco, Brazil. Prior to sample collection, the individual was informed about the study and consent. This work followed the ethical principles in human experimentation adopted by the local Research Ethics Committee (CEP/CPqAM: 33/10, CAAE: 0032.0.095.000-10).
IgG purification was performed by affinity chromatography with a Protein G column (HiTrap rProtein G 0.7 Â 2.5 cm, GE Healthcare) connected to an Äkta Purifier (GE Healthcare). Sample was diluted 10-fold in 20 mM sodium phosphate pH 7.0 and soluble fraction was obtained after a centrifugation step at 16,000g for 10 min at 4°C. Following an equilibration step with the same buffer, 4 mg of protein were applied onto the column; analyte was eluted with 100 mM glycine-HCl pH 2.1 and its pH was immediately neutralized with 1 M Tris pH 9.0. The chromatographic run was carried out at room temperature, a flow rate of 1 mL/min and absorbance monitoring at 280 nm. Pool of purified IgG was prepared as previously described for the immunoprecipitation experiments [1] . Fig. 2 . Cross-linking immunoprecipitation assay performed with 50% binding capacity of 10 mL magnetic beads (65 mg of IgG), followed by addition of 37.5 mg of T. cruzi extract (ca. 1:0.5 ratio). Ab: original antibody purified sample; AbN: fraction with eventual non-retained antibody after 2 h of incubation for antibody immobilization; C: fraction collected immediately after cross-linking reaction; TP: total parasite protein; NR: fraction containing non-retained parasite proteins; R: fraction with retained proteins after 2 h incubation at 37°C.
Cross-linking immunoprecipitation assays
The immunoprecipitation experiments were performed with either 10 or 50 mL of ressuspended slurry, which were equivalent to 2 or 10 mL of Protein G magnetic beads (GE Healthcare). Particles were initially equilibrated with TBS (50 mM Tris, 150 mM NaCl, pH 7.5). Next, 100 mL of IgG were applied into the system and maintained at room temperature for 1 or 2 h, respectively; antibodies eventually not bound to Protein G were collected (AbN). After washing the magnetic beads with TBS, 200 mM triethanolamine pH 8.9 were added; beads were homogenized and the solution was rapidly discarded. Following, cross-linking reaction was performed with 50 mM of dimethyl pimelimidate (DMP) (Sigma-Aldrich, Saint Louis, EUA) in triethanolamine for 1 h at room temperature. Beads were then ressuspended with 200 mM triethanolamine pH 8.9. The solution was removed and the reaction was blocked by adding 100 mM ethanolamine pH 8.9. After 15 min, supernatant was removed and the eventually not retained antibodies were eluted with 0.1 M glycine-HCl pH 2.9 added 2 M urea. This fraction was collected and identified as "C". Beads were then equilibrated twice with TBS and the parasite protein extracts diluted in TBS were added; incubations were carried out at room temperature or 37°C for 1 h or 2 h, respectively. T. cruzi proteins not retained were collected and beads washed thrice with TBS added 2 M urea. Next, immunoreactive proteins were eluted twice with 100 m L of 100 mM glycine-HCl pH 2.9 under moderate shaking by inversion for 10 min; both fractions were pooled. Unless otherwise specified, incubations were performed with 500 mL of solution and incubations were carried out under moderate shaking by inversion.
SDS-PAGE under reducing conditions
Electrophoresis were performed with stacking and separating gels composed by 4% and 12% of acrylamide (30% T, 2.67% C; Biorad, Hercules, USA). Gels were prepared with 0.5 M Tris-HCl pH 6.8 and 1.5 M Tris-HCl pH 8.8, respectively, to a final concentration of 0.1% SDS. Polymerization and runs were performed in Vert-i10 system (Loccus Biotechnology, São Paulo, Brazil). Samples were solubilized in modified Laemmli [5] buffer (0.06 M Tris-HCl pH 6.8, 2% SDS, 100 mM dithiothreitol, 10% glycerol, 0.025% bromophenol blue), boiled for 5 min, centrifuged at 16,000g for 2 min and then applied onto the gels. Electrophoreses were performed at constant 200 V in Tris-glycine buffer (25 mM tris, 192 mM glycine, 0.1% SDS pH 8.3). GE Healthcare mixture of standard molecular mass was used as reference. At the end of electrophoresis, gels were stained by silver impregnation. Polypeptide chains fixation were carried out overnight with 30% (v/v) ethanol and 10% (v/v) acetic acid. Next, a sensitization step was performed with 30% (v/v) ethanol, 0.2% (w/v) sodium thiosulfate and 12% (w/v) sodium acetate trihydrate for 30 min. Gels were then washed thrice (2 min each) with deionized water and incubated for 20 min in 0.25% (w/v) silver nitrate and 0.04% (v/v) 37% formaldehyde. Following three washes of 20 s each, polypeptide chains were detected with 2.5% (w/v) sodium carbonate, 0.02% (v/v) formaldehyde, 0.001% (w/v) sodium thiosulfate. The detections were carried out for 2 to 5. Next, this solution was discarded and the gels were maintained for 10 min in 1.5% (w/v) EDTA-Na2.2H 2 O [6] . Gel images were acquired using an ImageScanner III (GE Healthcare) and Adobe Photoshop Elements (Adobe Systems Inc.).
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